Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism

被引:410
作者
Volles, MJ
Lansbury, PT
机构
[1] Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02139 USA
[2] Harvard Med Sch, Dept Neurol, Cambridge, MA 02139 USA
关键词
D O I
10.1021/bi0121353
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Two mutations in the protein alpha-synuclein (A30P and A53T) are linked to an autosomal dominant form of Parkinson's disease. Both mutations accelerate the formation of prefibrillar oligomers (protofibrils) in vitro, but the mechanism by which they promote toxicity is unknown. Protofibrils of wild-type alpha-synuclein bind and permeabilize acidic phospholipid vesicles. This study examines the relative membrane permeabilizing activities of the wild type, mutant, and mouse variants of protofibrillar alpha-synuclein and the mechanism of membrane permeabilization. Protofibrillar A30P, A53T, and mouse variants were each found to have greater permeabilizing activities per mole than the wild-type protein. The leakage of vesicular contents induced by protofibrillar alpha-synuclein exhibits a strong preference for low-molecular mass molecules, suggesting a pore-like mechanism for permeabilization. Under conditions in which the vesicular membrane is less stable (lack of calcium as a phospholipid counterion), protofibril permeabilization is less size-selective and monomeric alpha-synuclein can permeabilize via a detergent-like mechanism. We conclude that the pathogenesis of Parkinson's disease may involve membrane permeabilization by protofibrillar alpha-synuclein, the extent of which will be strongly dependent on the in vivo conditions.
引用
收藏
页码:4595 / 4602
页数:8
相关论文
共 42 条
[1]  
BARTLETT GR, 1959, J BIOL CHEM, V234, P466
[2]   Residual structure and dynamics in Parkinson's disease-associated mutants of α-synuclein [J].
Bussell, R ;
Eliezer, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (49) :45996-46003
[3]   Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid [J].
Conway, KA ;
Harper, JD ;
Lansbury, PT .
BIOCHEMISTRY, 2000, 39 (10) :2552-2563
[4]   Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease:: Implications for pathogenesis and therapy [J].
Conway, KA ;
Lee, SJ ;
Rochet, JC ;
Ding, TT ;
Williamson, RE ;
Lansbury, PT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (02) :571-576
[5]   Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease [J].
Conway, KA ;
Harper, JD ;
Lansbury, PT .
NATURE MEDICINE, 1998, 4 (11) :1318-1320
[6]   Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct [J].
Conway, KA ;
Rochet, JC ;
Bieganski, RM ;
Lansbury, PT .
SCIENCE, 2001, 294 (5545) :1346-1349
[7]   Stabilization of α-synuclein secondary structure upon binding to synthetic membranes [J].
Davidson, WS ;
Jonas, A ;
Clayton, DF ;
George, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) :9443-9449
[8]   ANTIMICROBIAL PEPTIDE MAGAININ-I FROM XENOPUS SKIN FORMS ANION-PERMEABLE CHANNELS IN PLANAR LIPID BILAYERS [J].
DUCLOHIER, H ;
MOLLE, G ;
SPACH, G .
BIOPHYSICAL JOURNAL, 1989, 56 (05) :1017-1021
[9]   Conformational properties of α-synuclein in its free and lipid-associated states [J].
Eliezer, D ;
Kutluay, E ;
Bussell, R ;
Browne, G .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 307 (04) :1061-1073
[10]  
Farooqui AA, 1998, CELL MOL NEUROBIOL, V18, P599, DOI 10.1023/A:1020261600498